Engineered immune cells take on Hard-to-Treat colon cancer

NCT ID NCT05759728

Recruiting now Disease control Sponsor: Carina Biotech Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new treatment called CNA3103 for people with metastatic colorectal cancer that has spread and not responded well to standard treatments. CNA3103 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The study will enroll about 45 participants to find the safest dose and see if the therapy can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CNA3103 (a personalized CAR-T cell therapy targeting LGR5)
What this could lead to: If it works, this could point toward a new treatment option for people with metastatic colorectal cancer that has not responded to standard therapies.
What could go wrong: This is a very early (Phase 1/2a) and small trial (45 people). CAR-T therapies can cause severe side effects like cytokine release syndrome, and it is unknown if CNA3103 will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER METASTATIC

Contacts and locations

Locations

Carina Biotech Investigators
RECRUITING

Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.